(Photo Courtesy: www.schott.com)
In April, West Pharmaceuticals, a manufacturer of drug administration systems and components, held several seminars across Indian cities to discuss its exclusive product -- Daikyo Crystal Zenith (CZ), which it claims will be the new life cycle solution for drug containment in the pharma industry, seen as an alternative to traditional glass.
Crystal Zenith components are made of Cyclic Olefin Polymer (CoP) material, which is said to be more inert than glass.
West said that this new containment solution will address issues of breakage, protein aggregation, delamination, and reactions with tungsten or silica, usually associated with glass.
Glass recalls were maximum in 2011, followed by 2014. Glass recalls have maximum impact on R&D plans affecting companies' competitive advantage. Consequently, the company experiences major revenue loss, impacting patient-access thereby promoting negative corporate image.